About Retatrutide
What is Retatrutide?
Retatrutide (CAS 2381089-83-2; also LY3437943) is a synthetic 39-amino-acid peptide designed as a triple agonist of three metabolic receptors: GIP, GLP-1, and glucagon (GCG). A C20 fatty diacid on the backbone extends plasma half-life, which is why research papers often discuss weekly dosing schedules.
Werhner Lab supplies retatrutide as lyophilised powder in 15 mg and 30 mg vials.
CAS: 2381089-83-2. Alternate ID: LY3437943. Molecular weight: ~4731 g/mol. Receptor profile: GIP-R, GLP-1R, and GCG-R at the same time.
How Retatrutide is studied in the literature
The literature focuses on triple-receptor pharmacology and preclinical metabolic models. The following is scientific background only. It does not claim what Werhner Lab material will do in any person.
Body composition and energy-expenditure research
In metabolic models, retatrutide is studied for effects on body composition, adiposity, and energy-expenditure pathways. The question is how simultaneous GIP-R, GLP-1R, and GCG-R activation compares with single- and dual-receptor agonists.
Glucose-regulation pathways
It is also studied in glucose-regulation and incretin-signalling models, including dose-dependent activity at all three target receptors.
Within the incretin class — how Retatrutide differs
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor activation | GLP-1R only | GIP-R + GLP-1R | GIP-R + GLP-1R + GCG-R |
| Amino acids | 31 | 39 | 39 |
| Distinct mechanism | Fatty-acid extension on GLP-1R | Dual incretin | Glucagon arm adds hepatic glucose output and energy-expenditure signals |
The glucagon-receptor arm is the distinguishing feature. Neither semaglutide nor tirzepatide activates GCG-R. In research that matters because glucagon agonism is linked to hepatic glucose production and thermogenesis — an energy-expenditure component that single- and dual-agonists lack.
Research areas
- Comparative in-vitro binding and signalling at GIP, GLP-1, and glucagon receptors
- Preclinical metabolic models of body composition and energy expenditure
- Comparison with single- and dual-agonist compounds (semaglutide, tirzepatide)
- Lipid metabolism and hepatic glucose-output pathways (glucagon arm)
- Formulation and stability of long-acting peptide analogues
Specifications
| CAS | 2381089-83-2 |
| Alternate ID | LY3437943 |
| Molecular weight | ~4731 g/mol |
| Receptor profile | Triple agonist: GIP-R / GLP-1R / GCG-R |
| Purity | ≥ 97.5% (supplier batch spec; CoA per lot) |
| Form | Lyophilised powder in a sealed glass vial |
| Sizes | 15 mg, 30 mg |
Storage
Lyophilised powder: −20°C long term. 2–8°C short term before reconstitution.
Reconstituted: 2–8°C; use within your lab window. Do not freeze after reconstitution unless the protocol requires it.
Quality
- Each batch ships to a stated purity specification
- Lot CoA documents identity and purity
- Use batch numbers RT15-7741 / RT30-5268 when requesting files
Important notice — Research Use Only
Retatrutide is supplied by Werhner Lab strictly as a laboratory research compound. Literature context is background only, not a medical claim, and does not describe effects in any individual. Not a medicine, supplement, or cosmetic. Not offered for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. Laboratory research only. Not for human consumption.